Oramed Pharmaceuticals Inc.

Director's Dealing • Feb 18, 2021

Instruction 1(b).

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

FORM 4	UNITED STATES SECURITIES AND EXCHANGE COMMISSION
--------	--------------------------------------------------

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

											or Section 30(h) of the Investment Company Act of 1940
1. Name and Address of Reporting Person* RAKIN KEVIN					2. Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC. [ ORMP ]									(Check all applicable) X Director	5. Relationship of Reporting Person(s) to Issuer Officer (give title		10% Owner
																		Other (specify
(Last)		(First)	(Middle)					3. Date of Earliest Transaction (Month/Day/Year)				below)			below)
36 CHURCH LANE					02/17/2021
(Street)					4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)
WESTPORT		CT	06880												X Form filed by One Reporting Person
														Form filed by More than One Reporting Person
(City)		(State)	(Zip)
			Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)							2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 5) 8)			4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and				5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
									Code V		Amount	(A) or (D)		Price		Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)
			Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned								(e.g., puts, calls, warrants, options, convertible securities)
1. Title of 2. Derivative Security (Instr. 3)	Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code V		(A)	(D)	Date Exercisable		Expiration Date	Title		Amount or Number of Shares
Stock Option	\$11.33	02/17/2021			(1) A		15,000		(1)		02/17/2031 Common

Explanation of Responses:

(right to buy)

1. The Stock Option will vest in 4 equal installments as follows: 3,750 shall vest on each of December 31, 2021, December 31, 2022, December 31, 2023 and December 31, 2024.

/s/ Kevin Rakin 02/17/2021

Stock 15,000 \$⁰ 15,000 ^D

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\$11.33 02/17/2021 A

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.